Updates for Health Providers on Monoclonal Antibodies for COVID-19: Less Promising Adjunct and Never an Alternative to Vaccinations

Am J Med. 2022 May;135(5):547-549. doi: 10.1016/j.amjmed.2021.12.019. Epub 2022 Jan 31.

Authors

Maja Berges¹, Keith Foster¹, Jennifer Foster¹, Lisa Martinez¹, Sean Martinez¹, Benjamin Fiedler¹, David L DeMets², Dennis G Maki², Charles H Hennekens³

Affiliations

¹ Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
² University of Wisconsin School of Medicine and Public Health, Madison.
³ Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. Electronic address: PROFCHHMD@prodigy.net.

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological*
COVID-19*
Humans
SARS-CoV-2
Vaccination

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological